Education
About Us
Working with TipRanks
Follow Us
Innate Pharma SA (FR:IPH)
:IPH
Earnings Data
Report Date
Sep 17, 2025Before Open (Confirmed)
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.33Last Year’s EPS
-0.31Same Quarter Last Year
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
Innate Pharma showcased significant progress in advancing their clinical pipeline, particularly with the recruitment and dosing of key assets like IPH65 and IPH45, and the FDA breakthrough designation for lacutamab. Financial stability and strategic focus on NK cell engagers and ADCs were emphasized. However, challenges remain with reduced R&D expenses, ongoing partnering discussions for lacutamab, and the shift in focus for IPH6401. Overall, the highlights and achievements appear to outweigh the lowlights.Company Guidance -
Q4 2024
Phase 1 Dose Finding Trial Recruitment for IPH65
The first patients were recruited into the Phase 1 dose finding trial for IPH65 in the first half of 2024, marking a critical step in its clinical development.
FDA Breakthrough Therapy Designation for Lacutamab
Lacutamab received FDA breakthrough therapy designation, bringing it closer to potential accelerated approval for treating Sezary syndrome.
First Patients Dosed for IPH45
The first patients were dosed for the Nectin-4 targeted ADC, IPH45, in January 2025, following the IND clearance in September 2024.
Strong Pipeline and Strategic Focus
Innate Pharma is advancing a robust pipeline with eight innovative assets in the clinic, focusing on NK cell engagers, ADCs, and late-stage assets like lacutamab.
Financial Stability Through Mid-2026
Cash, cash equivalent, short-term investments, and financial assets amounted to EUR91.1 million as of December 31, 2024, providing sufficient funds through mid-2026.
FR:IPH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
FR:IPH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 27, 2025 | €1.86 | €1.88 | +0.91% |
Sep 12, 2024 | €2.18 | €2.12 | -2.75% |
Mar 21, 2024 | €2.19 | €2.17 | -0.69% |
Sep 14, 2023 | €2.83 | €2.78 | -1.77% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Innate Pharma SA (FR:IPH) report earnings?
Innate Pharma SA (FR:IPH) is schdueled to report earning on Sep 17, 2025, Before Open (Confirmed).
What is Innate Pharma SA (FR:IPH) earnings time?
Innate Pharma SA (FR:IPH) earnings time is at Sep 17, 2025, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Innate Pharma SA stock?
The P/E ratio of Innate Pharma SA is N/A.
What is FR:IPH EPS forecast?
FR:IPH EPS forecast for the fiscal quarter 2025 (Q2) is -0.33.